Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.
Yingmiao Liu(Duke Medical Center), Andrew B. Nixon(Duke University), Manoj A. Jivani(Tracon Pharmaceuticals (United States)), Zhenhua Yuan(Duke University), Herbert I. Hurwitz(Duke Medical Center), Toni K. Choueiri(Harvard University), Steven Attia(Mayo Clinic in Florida), Charles P. Theuer(Halozyme Therapeutics (United States)), Mark D. Starr(Duke Medical Center), John C. Brady(Duke Medical Center), Bonne J. Adams(Tracon Pharmaceuticals (United States)), Delia Alvarez(Tracon Pharmaceuticals (United States)), Dadong Zhang(Duke Cancer Institute), Kouros Owzar(Duke University)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k